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Survival Rates for Patients With Barrett High-grade Dysplasia and
Esophageal Adenocarcinoma With or Without Human Papillomavirus
Infection
Abstract

IMPORTANCE High-risk human papillomavirus (HPV) has been associated with Barrett dysplasia and
esophageal adenocarcinoma. Nevertheless, the prognostic significance of esophageal tumor HPV status is
unknown.
OBJECTIVE To determine the association between HPV infection and related biomarkers in high-grade
dysplasia or esophageal adenocarcinoma and survival.
DESIGN, SETTING, AND PARTICIPANTS Retrospective case-control study. The hypothesis was that
HPV-associated esophageal tumors would show a favorable prognosis (as in viral-positive head and neck
cancers). Pretreatment biopsies were used for HPV DNA determination via polymerase chain reaction, in situ
hybridization for E6 and E7 messenger RNA (mRNA), and immunohistochemistry for the proteins
p16INK4A and p53. Sequencing of TP53 was also undertaken. The study took place at secondary and tertiary
referral centers, with 151 patients assessed for eligibility and 9 excluded. The study period was from December
1, 2002, to November 28, 2017.
MAIN OUTCOMES AND MEASURES Disease-free survival (DFS) and overall survival (OS).
RESULTS
Among 142 patients with high-grade dysplasia or esophageal adenocarcinoma (126 [88.7%] male; mean [SD]
age, 66.0 [12.1] years; 142 [100%] white), 37 were HPV positive and 105 were HPV negative. Patients who
were HPV positive mostly had high p16INK4A expression, low p53 expression, and wild-type TP53. There
were more Tis, T1, and T2 tumors in HPV-positive patients compared with HPV-negative patients (75.7%vs
54.3%; difference, 21.4%; 95%CI, 4.6%-38.2%; P = .02). Mean DFS was superior in the HPV-positive group
(40.3 vs 24.1 months; difference, 16.2 months; 95%CI, 5.7-26.8; P = .003) as was OS (43.7 vs 29.8 months;
difference, 13.9 months; 95% CI, 3.6-24.3; P = .009). Recurrence or progression was reduced in the HPVpositive cohort (24.3%vs 58.1%; difference, −33.8%; 95%CI, −50.5%to −17.0%; P < .001) as was distant
metastasis (8.1%vs 27.6%; difference, −19.5%; 95%CI, −31.8%to −7.2%; P = .02) and death from esophageal
adenocarcinoma (13.5%vs 36.2%; difference, −22.7%; 95%CI, −37.0% to −8.3%; P = .01). Positive results for
HPV and transcriptionally active virus were both associated with a superior DFS (hazard ratio [HR], 0.33;
95%CI, 0.16-0.67; P = .002 and HR, 0.44; 95%CI, 0.22-0.88; P = .02, respectively [log-rank test]). Positivity
for E6 and E7 mRNA, high p16INK4A expression, and low p53 expression were not associated with improved
DFS. On multivariate analysis, superior DFS was demonstrated for HPV (HR, 0.39; 95%CI, 0.18-0.85; P =
.02), biologically active virus (HR, 0.36; 95%CI, 0.15-0.86; P = .02), E6 and E7 mRNA (HR, 0.36; 95%CI,
0.14-0.96; P = .04), and high p16 expression (HR, 0.49; 95%CI, 0.27-0.89; P = .02).
CONCLUSIONS AND RELEVANCE Barrett high-grade dysplasia and esophageal adenocarcinoma in
patients who are positive for HPV are distinct biological entities with a favorable prognosis compared with
viral-negative esophageal tumors. Confirmation of these findings in larger cohorts with more advanced disease
could present an opportunity for treatment de-escalation in the hope of reducing toxic effects without
deleteriously affecting survival.
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Abstract

Key Points

IMPORTANCE High-risk human papillomavirus (HPV) has been associated with Barrett dysplasia
and esophageal adenocarcinoma. Nevertheless, the prognostic significance of esophageal tumor
HPV status is unknown.

Question What is the prognostic
significance of esophageal tumor human
papillomavirus (HPV) status?
Findings In this case-control study
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MAIN OUTCOMES AND MEASURES Disease-free survival (DFS) and overall survival (OS).

and esophageal adenocarcinoma in
patients who are HPV positive have a

RESULTS Among 142 patients with high-grade dysplasia or esophageal adenocarcinoma (126
[88.7%] male; mean [SD] age, 66.0 [12.1] years; 142 [100%] white), 37 were HPV positive and 105
were HPV negative. Patients who were HPV positive mostly had high p16INK4A expression, low p53
expression, and wild-type TP53. There were more Tis, T1, and T2 tumors in HPV-positive patients

favorable prognosis compared with
viral-negative esophageal tumors and
may benefit from treatment
de-escalation.

compared with HPV-negative patients (75.7% vs 54.3%; difference, 21.4%; 95% CI, 4.6%-38.2%;
P = .02). Mean DFS was superior in the HPV-positive group (40.3 vs 24.1 months; difference, 16.2
months; 95% CI, 5.7-26.8; P = .003) as was OS (43.7 vs 29.8 months; difference, 13.9 months; 95%
CI, 3.6-24.3; P = .009). Recurrence or progression was reduced in the HPV-positive cohort (24.3% vs
58.1%; difference, −33.8%; 95% CI, −50.5% to −17.0%; P < .001) as was distant metastasis (8.1% vs
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27.6%; difference, −19.5%; 95% CI, −31.8% to −7.2%; P = .02) and death from esophageal
adenocarcinoma (13.5% vs 36.2%; difference, −22.7%; 95% CI, −37.0% to −8.3%; P = .01). Positive
results for HPV and transcriptionally active virus were both associated with a superior DFS (hazard
ratio [HR], 0.33; 95% CI, 0.16-0.67; P = .002 and HR, 0.44; 95% CI, 0.22-0.88; P = .02, respectively
[log-rank test]). Positivity for E6 and E7 mRNA, high p16INK4A expression, and low p53 expression
were not associated with improved DFS. On multivariate analysis, superior DFS was demonstrated
for HPV (HR, 0.39; 95% CI, 0.18-0.85; P = .02), biologically active virus (HR, 0.36; 95% CI, 0.15-0.86;
P = .02), E6 and E7 mRNA (HR, 0.36; 95% CI, 0.14-0.96; P = .04), and high p16 expression (HR, 0.49;
95% CI, 0.27-0.89; P = .02).
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Abstract (continued)

CONCLUSIONS AND RELEVANCE Barrett high-grade dysplasia and esophageal adenocarcinoma in
patients who are positive for HPV are distinct biological entities with a favorable prognosis compared
with viral-negative esophageal tumors. Confirmation of these findings in larger cohorts with more
advanced disease could present an opportunity for treatment de-escalation in the hope of reducing
toxic effects without deleteriously affecting survival.
JAMA Network Open. 2018;1(4):e181054. doi:10.1001/jamanetworkopen.2018.1054

Introduction
Esophageal adenocarcinoma (EAC) is one of the fastest-growing and deadliest cancers in the Western
world,1,2 although recently the rate of increase has diminished and possibly plateaued in the United
States and Sweden.3,4 Currently, Barrett esophagus (BE) is the only recognized visible precursor
lesion for EAC. Intriguingly, these high rates of EAC have occurred against a backdrop of progressive
reduction in the risk estimate of malignancy associated with BE.5 In this regard, our discovery of a
strong association of transcriptionally active high-risk human papillomavirus (HPV) with a subset of
Barrett dysplasia (BD) and EAC5 may be relevant.
Increasing high-risk HPV viral load and integration status has been linked with more severe
disease along the Barrett metaplasia-dysplasia-adenocarcinoma sequence.6 Moreover, treatment
failure after endoscopic ablation of BD or EAC is predicted by persistent high-risk HPV infection and
overexpression of the p53 gene (TP53).7 We also discovered that HPV-positive EAC is molecularly distinct
from HPV-negative EAC, indicating different biological mechanisms of tumor genesis.8 Hybrid sequences
containing HPV-16 and the human genome have been identified, indicating a host-viral interaction.8
Aberrations of the retinoblastoma protein (pRb) pathway, ie, upregulation of p16INK4A and
downregulation of pRb, as well as wild-type TP53 are hallmarks of active HPV involvement in BD and
EAC. Additionally, the transformation-specific combination of high p16 expression and low pRb
expression, which is a feature of HPV-driven lesions, has been identified in a significant proportion of
virally positive BD and EAC.9
Ability to detect HPV in earlier negative studies and more recent investigations may have been
hampered by poor tissue classification and suboptimal testing methods. This is further exacerbated
by the low HPV viral load in esophageal tissue. Some of these misclassified negative studies only used
nondysplastic BE. Metaplastic tissue is not associated with HPV. Racial or geographic variations can
also account for this anomaly.10-14 Interestingly, a systematic review has reported HPV prevalence
rates of 35% in 174 patients with EAC, similar to our findings.15 Another systematic review that
included 19 studies concluded that the pooled prevalence of HPV in EAC was 13%, suggesting the low
prevalence rate may have been caused by small sample sizes and compromised detection methods.16
It is well documented that patients with HPV-positive head and neck squamous cell carcinoma
(HNSCC) have an improved rate of overall survival (OS) (hazard ratio [HR], 0.7; 95% CI, 0.5-1.0) and a
reduced risk of recurrence (HR, 0.5; 95% CI, 0.4-0.7) compared with viral-negative tumors.17 A
meta-analysis reported a 74% improved disease-free survival (DFS) and 53% better OS in
HPV-associated HNSCC vs HPV-negative HNSCC.18 We therefore hypothesized that HPV-associated
EAC and high-grade dysplasia (HGD) would show a similar favorable prognosis compared with
HPV-negative esophageal lesions.

Methods
Study Design and Population
This retrospective case-control study followed the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) reporting guideline. Eligible patients were those with HGD or EAC
(Siewert classification type I or II) deemed suitable for treatment, ie, for endotherapy (endoscopic
JAMA Network Open. 2018;1(4):e181054. doi:10.1001/jamanetworkopen.2018.1054

Downloaded From: https://jamanetwork.com/ by a University of Wollongong User on 05/27/2019

August 3, 2018

2/12

JAMA Network Open | Gastroenterology and Hepatology

Survival in High-grade Barrett Dysplasia and Esophageal Cancer With or Without HPV

mucosal resection [EMR] and/or radiofrequency ablation [RFA]) or esophagectomy with or without
neoadjuvant chemotherapy and/or radiotherapy. The study period was from December 1, 2002, to
November 28, 2017, and patients were enrolled from a tertiary referral center, Bankstown-Lidcombe
Hospital, Sydney, Australia (n = 139), and a regional health care center, Launceston General Hospital,
Launceston, Tasmania, Australia (n = 3). Demographic and clinical data were obtained from a
prospectively maintained database. Inclusion and exclusion criteria have been previously documented.9
Pretreatment tissue was prospectively collected in 94 patients (both fresh frozen and formalin-fixed
paraffin-embedded [FFPE]) and retrospectively retrieved (FFPE only) from the remaining 48 patients.
Oral and written informed consent were obtained from participants prior to the investigation. This study
was approved by the Human Research Ethics Committee, Tasmania, and South Western Sydney Local
Health Network.

Endotherapy and/or Esophagectomy
Staging endoscopic ultrasound examination was performed on all patients. Patients with nodular or
ulcerating lesions without lymph node involvement underwent EMR. Apart from endoscopic
ultrasound, positron emission tomography, computed tomography, and laparoscopy were
performed as staging investigations in patients considered candidates for esophagectomy.
Circumferential and focal RFA were used to ablate flat lesions to achieve complete eradication.
Patients were scheduled to return for 3-, 6-, 9-, and 12-month follow-up endoscopy and biopsy.
Residual lesions were ablated and nodules subjected to EMR.
Patients with adenocarcinoma invading beyond the muscularis mucosa into the submucosa
(T1b lesions) were excluded from endotherapy and underwent esophagectomy with D2 lymph node
dissection. Siewert type I tumors were subjected to Ivor Lewis esophagogastrectomy and Siewert
type II cancers to either radical total gastrectomy including lower esophagus or Ivor Lewis
esophagectomy depending on the patient’s build.
Staging was performed according to the seventh edition of the Cancer Staging Manual by the
American Joint Committee on Cancer.19 Patients with locally advanced disease (T3 or T4 N0 or any T
stage with N1) were potential candidates for neoadjuvant or adjuvant treatment. After treatment,
repeat staging was done to exclude metastatic disease prior to proceeding to esophagectomy. As
such, 14 patients did not undergo esophagectomy due to tumor-related factors or patient refusal.
Nevertheless, they were included in the analysis as they had undergone radiotherapy and/or
chemotherapy.

Laboratory Studies
Detection of HPV in genomic DNA extracted from fresh frozen or formalin-fixed biopsy tissue was
performed by nested polymerase chain reaction (PCR) amplification of a conserved viral L1 gene
using MY09 and MY11 and GP5+ and GP6+ primers for both high-risk and low-risk HPV as previously
published.5 To minimize contamination, separate rooms were used for reaction preparation,
template handling, performing nested reactions, and post-PCR analysis. Routine decontamination by
UV irradiation was performed in the DNA-free PCR hood before each run. To guard against systematic
contamination of PCR reagent, appropriate positive (HPV-16–positive cervical cancer) and negative
(deionized water and PCR master mix without template) controls were included in each step of the
PCR process. Genotypes of HPV were determined by sequencing.5 Real-time PCR assays measuring
HPV E6 and E7 copy numbers were performed to determine viral load using genotype-specific
HPV-16 and HPV-18 primers.6
In situ hybridization (ISH) of RNA for high-risk HPV-16 and HPV-18 E6 and E7 messenger RNA
(mRNA) was performed manually using the RNAscope 2.5 High-Definition Assay (Advanced Cell
Diagnostics Inc) with a cocktail of probes targeting 18 high-risk HPV types (HPV types 16, 18, 26, 31,
33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82) according to the manufacturer’s instructions.9
Negative and positive controls were probes recognizing the bacterial gene dapB and the endogenous
ubiquitin C mRNA, respectively. In addition, cervical cancer tissue, HNSCC samples, BE and BD, EAC,
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and esophageal squamous cell carcinoma (ESCC), which all had detectable transcriptionally active
HPV (DNA positive by PCR and the presence of ⱖ1 of 2 markers of biological activity, ie, E6 and E7
mRNA and/or p16INK4A), served as positive controls. We used HNSCC, BE and BD, EAC, and ESCC
devoid of virus as negative controls. Positivity was defined as the presence of punctuate cytoplasmic
and/or nuclear staining that exceeded the dapB (negative control) signal. Expression of the p16INK4A
and p53 proteins was assessed by immunohistochemistry (IHC) on FFPE tissue using EnVision FLEX
Mini Kits and CINtec Histology Kits (monoclonal mouse anti–human p16INK4A antibody, clone E6H4)
(mtm laboratories), respectively, using appropriate positive and negative controls.9 All IHC scoring of
slides was independently performed by 2 experienced gastrointestinal pathologists blinded to the
virological status and the clinical outcome of patients. For p16INK4A, at least moderate staining of
both nucleus and cytoplasm in more than 25% of esophageal dysplastic or tumor tissue was
considered as p16 overexpression. Staining of 25% or less was deemed low expression. Using this
criterion, we have demonstrated that high p16 expression is associated with HPV-associated BD and
EAC with reasonable sensitivity and specificity as others have in HNSCC.9,20 In the case of p53,
intense nuclear staining of more than 10% of esophageal cells was considered overexpression.7,9
Mutations of TP53 were confirmed by sequencing of the gene using the semiconductor-based Ion
Torrent sequencing platform (ThermoFisher) according to the manufacturer’s instructions as
previously published.9

Study End Points and Statistical Analysis
The primary end points were DFS from the time of diagnosis to the date of first local, regional, or
distant failure and OS, defined as time between diagnosis to the date of death or last follow-up.
Differences between HPV-positive and HPV-negative cases in regard to baseline characteristics
were assessed using the 2-sample t test for comparing the mean values between the 2 groups in
regard to all numerical data. A χ2 analysis was used for evaluating the association between the binary
measurements in the viral-positive and viral-negative groups. Survival analysis was conducted using
the Kaplan-Meier method to estimate the DFS and OS of the 5 HPV variables, ie, viral DNA status,
transcriptionally active HPV, E6 and E7 mRNA, p16, and p53. The log-rank test was used to analyze
the association between the HPV variables with DFS and OS. Cox proportional hazards regression
models were used to estimate the importance of these biomarkers for DFS and OS after adjusting for
age, sex, body mass index (calculated as weight in kilograms divided by height in meters squared),
history of smoking, excess alcohol use, medications (proton-pump inhibitors, nonsteroidal antiinflammatory drugs, or statins), T stage, N stage, surgical or endoscopic mucosal resection margin
status, degree of tumor differentiation, and neoadjuvant or adjuvant treatment (model 2). Because
viral status itself was associated with disease severity, adjusting for stage and treatment
(chemotherapy and/or radiotherapy) may have prevented identification of prognostic effects
derived exclusively from the 5 HPV variables. Therefore, additional Cox regression models were
applied with all of the above covariates but excluding T and N stages as well as chemotherapy and
radiotherapy (model 3). All statistical tests were performed using SAS statistical software version 9.4
(SAS Institute Inc), and the level of significance was set at .05 (2-sided).

Results
Patient Characteristics
A total of 142 patients were tested for HPV status, p16INK4A IHC, and E6 and E7 mRNA ISH (eFigure 1
in the Supplement). Of 142 patients (126 [88.7%] male; mean [SD] age, 66.0 [12.1] years; 142 [100%]
white), 37 were HPV positive and 105 were HPV negative. Mean (SD) follow-up time was 33.4 (28.0)
months (range, 2-159 months) for the whole study population and 43.8 (29.4) months (range, 3-159
months) for survivors.
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HPV DNA, E6 and E7 mRNA, p16INK4A, and p53 Status
Polymerase chain reaction analysis of HPV DNA was performed on all 142 patients with esophageal
lesions (38 HGD and 104 EAC). Thirty-seven patients (11 with HGD and 26 with EAC) had positive
results for HPV DNA; 33 had HPV-16, 1 had HPV-18, and the remaining 3 had low-risk types 6 and 11.
No multiple genotypes were detected in the same patient. Amplifiable β-globin gene was present in
all specimens, and median (range) viral load was 0.1 copy per 10 cell genomic DNA (0-1.12 copies per
10 cell genome). All specimens with measurable viral load revealed coherence between genotypes
found on MY09 and MY11 and GP5+ and GP6+ PCR and those found in E6 and E7 analysis. In the 142
HGDs and EACs assessed, 33 of 34 high-risk HPV (types 16 and 18) (97.1%) had detectable viral load.
Among the 37 DNA-positive lesions, 18 (48.7%) had E6 and E7 mRNA detection by ISH and 19 (51.4%)
overexpressed p16INK4A. Eleven samples (29.7%) were positive for all 3 markers.
Demographic, clinical, and pathological data are compared between HPV-positive and
HPV-negative individuals with esophageal lesions in Table 1. Overexpression of p16INK4A and E6 and
E7 mRNA presence were significantly greater in the HPV-positive group compared with the viralnegative cohort. Of note, HPV-positive patients had more early-stage (Tis, T1, and T2) esophageal
lesions compared with viral-negative patients (75.7% vs 54.3%; difference, 21.4%; 95% CI,
4.6%-38.2%; P = .02), but nodal stage was similar between the groups. Most were stage N0 or N1 in
both the HPV-positive (89.2%) and viral-negative (89.5%) patients with HGD and EAC. No significant
differences were detected in any of the other clinical or pathological baseline characteristics. In the
transcriptionally active HPV-positive group (HPV positive with p16INK4A, HPV positive with E6 and E7
mRNA, or HPV positive with both p16INK4A and E6 and E7 mRNA), the patients were significantly
younger than the biologically inactive virus group (HPV positive without p16INK4A and/or E6 and E7
mRNA) (61.4 vs 67.2 years; difference, −5.8 years; 95% CI, −10.6 to −1.0 years; P = .02) (eTable in the
Supplement).

HPV Status and Survival
Table 2 depicts the mean follow-up, DFS, OS, and recurrence or progression rate for the HPV-positive
patients with HGD and EAC and the viral-negative groups. Mean (SD) DFS was 40.3 (33.8) months in
the HPV-positive esophageal lesion group and 24.1 (25.5) months in the HPV-negative cohort
(difference, 16.2 months; 95% CI, 5.7-26.8 months; P = .003). Similarly, mean (SD) OS was 43.7 (32.9)
months in the viral-positive group compared with 29.8 (25.3) months in the HPV-negative patients
(difference, 13.9 months; 95% CI, 3.6 to 24.3 months; P = .009). As expected, recurrence or
progression was much reduced in the HPV-positive cohort compared with the HPV-negative cohort
(9 of 37 [24.3%] vs 61 of 105 [58.1%]; difference, −33.8%; 95% CI, −50.5% to −17.0%; P < .001).
Recurrence per se was almost a third less in the HPV-positive patients in comparison with
HPV-negative patients (6 of 37 [16.2%] vs 46 of 105 [43.8%]; difference, −27.6%; 95% CI, −42.8% to
−12.4%; P = .003). There appeared to be better (although nonsignificant) local and regional control
for the HPV-positive patients compared with viral-negative individuals (6 of 37 [16.2%] vs 32 of 105
[30.5%]; difference, −14.3%; 95% CI, −29.0% to 0.5%; P = .09). Significantly, reduced distant
metastasis was observed in the HPV-positive group (3 of 37 [8.1%] vs 29 of 105 [27.6%]; difference,
−19.5%; 95% CI, −31.8% to −7.2%; P = .02) as were deaths from EAC (5 of 37 [13.5%] vs 38 of 105
[36.2%]; difference, −22.7%; 95% CI, −37.0% to −8.3%; P = .01).
Kaplan-Meier graphs for DFS and OS of patients categorized by HPV, transcriptionally active
virus, E6 and E7 mRNA, and high expression of p16 and low expression of p53 are shown in the
Figure and in eFigure 1, eFigure 2, and eFigure 3 in the Supplement. The log-rank test revealed that
HPV status and transcriptionally active viral presence were individually associated with a superior
DFS of 67% (HR, 0.33; 95% CI, 0.16-0.67; P = .002) and 56% (HR, 0.44; 95% CI, 0.22-0.88; P = .02),
respectively (model 1 in Table 3). Conversely, positive status for E6 and E7 mRNA, high expression
of p16INK4A, and low expression of p53 were not associated with improved DFS. Subsequently, Cox
proportional hazards models were used to estimate the importance of these biomarkers for DFS and
OS after adjusting for all the 14 variables mentioned under Study End Points and Statistical Analysis.
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This revealed statistically superior DFS for HPV (HR, 0.39; 95% CI, 0.18-0.85; P = .02), biologically
active virus (HR, 0.36; 95% CI, 0.15-0.86; P = .02), E6 and E7 mRNA (HR, 0.36; 95% CI, 0.14-0.96;
P = .04), and high p16 expression (HR, 0.49; 95% CI, 0.27-0.89; P = .02) (model 2 in Table 3).
In regard to OS, HPV status was not statistically associated with improved prognosis (HR, 0.54;
95% CI, 0.28-1.04; log-rank P = .06) (model 1 in Table 4).
As viral status itself was associated with disease severity and the likelihood of too many
covariates diluting the multivariate models, further analysis of these HPV-related factors was
undertaken using Cox models without adjustment for stage or treatment options (model 3 in Table 3
and Table 4). This resulted in a significantly enhanced DFS for HPV DNA positivity (HR, 0.36; 95%

Table 1. Demographic and Clinical Characteristics of the Study Population and Associated Tumors According
to Patient Group
No. (%)a
Patients With HPV-Positive
HGD or EAC (n = 37)

Patients With HPV-Negative
HGD or EAC (n = 105)

Male

33 (89.2)

93 (88.6)

Female

4 (10.8)

12 (11.4)

Characteristic

P Valueb

Sex
.92

Age, mean (SD) (range), y

65.2 (12.4) (33.0-89.0)

66.2 (12.0) (32.0-90.0)

.65

Body mass index, mean (SD)c

27.7 (5.7)

27.0 (5.1)

.53

Ever smoked

24 (64.9)

77 (73.3)

.33

Smoked >10 pack-yearsd

22/24 (91.7)

69/76 (90.8)

.90

Smoked >20 pack-yearsd

15/24 (62.5)

48/76 (63.2)

.95

Alcohol intake

26/36 (72.2)

75 (71.4)

.93

Excess alcohole

8/35 (22.9)

18 (17.1)

.45

Proton-pump inhibitors

28 (75.7)

75 (71.4)

.62

Nonsteroidal anti-inflammatory drugs

11 (29.7)

23 (21.9)

.34

Statins

11 (29.7)

31 (29.5)

.98

Esophagitis

4/36 (11.1)

14/104 (13.5)

.72

Hiatal hernia

21/36 (58.3)

49/101 (48.5)

.31

R0

26/29 (89.7)

61/75 (81.3)

R1 or R2

3/29 (10.3)

14/75 (18.7)

Well

3 (8.1)

5 (4.8)

Moderate

14 (37.8)

31 (29.5)

Poor

5 (13.5)

32 (30.5)

Not documented

15 (40.5)

37 (35.2)

Treatment endotherapy, EMR and RFA

17 (46.0)

41 (39.1)

.46

Esophagectomy

21 (56.8)

54 (51.4)

.58

Resection margin
.30

Histology, degree of differentiation

.22

Pathologic T stagef
Tis, T1, or T2

28 (75.7)

57 (54.3)

T3 or T4

9 (24.3)

48 (45.7)

N0-N1

33 (89.2)

94 (89.5)

N2-N3

4 (10.8)

11 (10.5)

M0

36 (97.3)

99 (94.3)

M1

1 (2.7)

6 (5.7)

Radiotherapy

8 (21.6)

28 (26.7)

.54

Chemotherapy

13 (35.1)

39 (37.1)

.83

.02

Abbreviations: EAC, esophageal adenocarcinoma;
EMR, endoscopic mucosal resection; HGD, high-grade
dysplasia; HPV, human papillomavirus; mRNA,
messenger RNA; RFA, radiofrequency ablation.
a

Denominators are listed when sample does not equal
full sample size.

b

Differences between HPV-positive vs HPV-negative
cases in regard to baseline characteristics were
assessed using 2-sample t test for all numerical data
and χ2 analysis for binary measurements.

c

Calculated as weight in kilograms divided by height
in meters squared.

d

A pack-year indicates smoking 1 pack of cigarettes
per day for a year.

e

Excess alcohol intake was defined as more than 21
units/wk for men and more than 14 units/wk
for women.

f

TNM classification as per the American Joint
Committee on Cancer’s Cancer Staging Manual,
7th Edition.

f

Pathologic N stage

.95

f

Pathologic M stage

.47

p16INK4a overexpression

19 (51.4)

34 (32.4)

.04

E6 and E7 mRNA positivity

18 (48.7)

6 (5.7)

<.001

Low p53 expression

23 (62.2)

40 (38.1)

.01
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CI, 0.17-0.77; P = .009), presence of transcriptionally active virus (HR, 0.31; 95% CI, 0.13-0.72;
P = .006), and E6 and E7 mRNA detection (HR, 0.32; 95% CI, 0.12-0.83; P = .02) (model 3 in Table 3).
Although the HR was lower for all 5 of these variables in relation to OS, none were statistically
significant (model 3 in Table 4).

Table 2. Comparison of Survival, Disease Relapse and Progression, and Site of Failure in HPV-Positive
and HPV-Negative Patients
No. (%)
Characteristic
Disease-free survival,
mean (SD), mo

Patients With HPV-Positive HGD
or EAC (n = 37)

Patients With HPV-Negative HGD
or EAC (n = 105)

P Valuea

40.3 (33.8)

24.1 (25.5)

.003

Overall survival, mean, mo

43.7 (32.9)

29.8 (25.3)

.009

Survival status (alive at last
follow-up)

26 (70.3)

58 (55.2)

.11

Recurrence or progression

9 (24.3)

61 (58.1)

<.001

Recurrence

6 (16.2)

46 (43.8)

.003

Local-regional failure

6 (16.2)

32 (30.5)

.09

Distant metastases

3 (8.1)

29 (27.6)

.02

Death due to EAC

5 (13.5)

38 (36.2)

.01

Abbreviations: EAC, esophageal adenocarcinoma;
HGD, high-grade dysplasia; HPV, human
papillomavirus.
a

Differences between HPV-positive vs HPV-negative
cases in regard to characteristics were assessed using
2-sample t test for all numerical data and χ2 analysis
for binary measurements.

Figure. Survival Among Patients With High-Grade Dysplasia or Esophageal Adenocarcinoma as a Function
of Human Papillomavirus (HPV) and Transcriptionally Active HPV
A Disease-free survival as a function of HPV status

B

1.0

0.8

Survival Probability

0.8

Survival Probability

Overall survival as a function of HPV status
1.0

HPV positive
0.6

0.4

HPV negative
0.2

HPV positive

0.6

0.4

HPV negative
0.2

P =.002

P =.06

Hazard ratio, 0.33 (95% CI, 0.16-0.67)

Hazard ratio, 0.54 (95% CI, 0.28-1.04)

0

0
0

20

40

60

80

100 120 140

0

20

40

Time, mo

60

80

100 120 140

Time, mo

No. at risk

No. at risk

HPV negative
HPV positive
C

105
37

56
29

40
28

33
28

33
28

33
28

33
28

HPV negative
HPV positive

105
37

69
29

58
25

49
25

34
25

34
25

34
25

D Overall survival as a function of

Disease-free survival as a function of
transcriptionally active HPV

transcriptionally active HPV

1.0

1.0

0.8

0.8

Survival Probability

Survival Probability

Transcriptionally active

Transcriptionally active

0.6

0.4

Not transcriptionally active
0.2

Not transcriptionally active
0.6

0.4

0.2
P =.02

P =.76

Hazard ratio, 0.44 (95% CI, 0.22-0.88)

Hazard ratio, 1.09 (95% CI, 0.61-1.98)

0

0
0

20

40

60

80

100 120 140

0

20

40

Time, mo
No. at risk
Not active
Active

60

80

100 120 140

Time, mo
No. at risk

112
30

62
23

49
21

44
21

44
21

44
21

44
21

Not active
Active

112
30

78
21

68
17

56
14

49
14

JAMA Network Open. 2018;1(4):e181054. doi:10.1001/jamanetworkopen.2018.1054

Downloaded From: https://jamanetwork.com/ by a University of Wollongong User on 05/27/2019

49
14

49
14

Of 142 patients with either high-grade dysplasia or
esophageal adenocarcinoma, 37 were HPV positive
and 105 were HPV negative (A and B). Thirty patients
had transcriptionally active HPV and 112 patients were
HPV negative or had HPV that was not
transcriptionally active (C and D).

August 3, 2018

7/12

JAMA Network Open | Gastroenterology and Hepatology

Survival in High-grade Barrett Dysplasia and Esophageal Cancer With or Without HPV

Next-Generation Sequencing of TP53
Of 142 HGD and EAC specimens, 132 (93.0%) were successfully sequenced, and in 104 of 132 (78.8%)
p53 IHC and sequencing data matched. Seventy-three (55.3%) harbored mutated TP53 and 59
(44.7%) had wild type. In the 73 specimens with TP53 mutations, 50 (68.5%) were missense
mutations present in the DNA binding domain (exons 5-8; aa102-292), 2 (2.7%) were missense
mutations in the oligomerization domain (exons 9-10), and 2 contained frameshift mutations in
exons 5 and 8 that induced a loss of both DNA binding and oligomerization domains. In 35 of 37
HPV-positive patients with HGD and EAC with successful sequencing, TP53 mutations were detected
in only 9 patients (25.7%) compared with 64 of 97 (66.0%) in the viral-negative group (difference,
−40.3%; 95% CI, −57.5% to −23.0%; P < .001 [Fisher exact test]).

Discussion
This is the first study, to our knowledge, to show improved survival associated with HPV-positive
HGD and EAC. Esophageal lesional HPV status and associated viral transcriptional markers, ie, E6 and
E7 mRNA (gold standard) and p16INK4A (surrogate marker) are associated with improved DFS in
patients with HGD and EAC. It was mainly due to a reduction in distant metastasis and possibly better
local and regional control in HPV-positive patients compared with HPV-negative patients. This
resulted in a lower mortality from EAC. Mean duration of OS was again significantly improved in the
HPV-positive group compared with the HPV-negative group. Nevertheless, the association of HPV
status with OS failed to reach significance by the log-rank test. Although 26 of 37 HPV-positive
individuals (70.3%) were alive at the end of the follow-up period compared with 58 of 105
HPV-negative individuals (55.2%), this was not statistically significant, possibly because of the

Table 3. Log-Rank and Multivariate Disease-Free Survival Analysis (Cox Regression)
Model 1a

Model 2b

Model 3c

Characteristic

Disease-Free Survival,
HR (95% CI)

Unadjusted
P Value

Disease-Free Survival,
HR (95% CI)

Adjusted
P Value

Disease-Free Survival,
HR (95% CI)

Adjusted
P Value

HPV positive

0.33 (0.16-0.67)

.002

0.39 (0.18-0.85)

.02

0.36 (0.17-0.77)

.009

Transcriptionally active HPV positive

0.44 (0.22-0.88)

.02

0.36 (0.15-0.86)

.02

0.31 (0.13-0.72)

.006

E6 and E7 mRNA positive

0.50 (0.24-1.05)

.07

0.36 (0.14-0.96)

.04

0.32 (0.12-0.83)

.02

High p16 expression

0.76 (0.46-1.25)

.28

0.49 (0.27-0.89)

.02

0.59 (0.34-1.02)

.06

Low p53 expression

0.85 (0.53-1.37)

.51

0.89 (0.53-1.51)

.66

0.84 (0.51-1.39)

.50

alcohol, proton-pump inhibitor use, nonsteroidal anti-inflammatory ingestion, statin
use, T stage, N stage, R0 resection margin, chemotherapy and radiotherapy, and tumor
differentiation.

Abbreviations: HPV, human papillomavirus, HR, hazard ratio; mRNA, messenger RNA.
a

Model 1 was a univariate analysis on each characteristic with disease-free survival.

b

In model 2, each characteristic was analyzed in a multivariate Cox regression
separately, adjusted by the following covariates: age, sex, body mass index (calculated
as weight in kilograms divided by height in meters squared), ever smoked, excess

c

Model 3 was the same as model 2 but excluded the following covariates in the
adjustment: T stage, N stage, chemotherapy, and radiotherapy.

Table 4. Log-Rank and Multivariate Overall Survival Analysis (Cox Regression)
Model 1a

Model 2b

Model 3c

Characteristic

Overall Survival,
HR (95% CI)

Unadjusted
P Value

Overall Survival,
HR (95% CI)

Adjusted
P Value

Overall Survival,
HR (95% CI)

Adjusted
P Value

HPV positive

0.54 (0.28-1.04)

.06

1.06 (0.46-2.46)

.89

0.64 (0.31-1.31)

.22

Transcriptionally active HPV positive

1.09 (0.61-1.98)

.76

1.80 (0.80-4.05)

.16

1.01 (0.52-1.98)

.98

E6 and E7 mRNA positive

1.23 (0.66-2.28)

.52

1.09 (0.47-2.51)

.84

1.02 (0.49-2.14)

.96

High p16 expression

1.32 (0.79-2.22)

.29

1.26 (0.66-2.40)

.48

1.06 (0.60-1.89)

.84

Low p53 expression

1.27 (0.76-2.12)

.37

1.62 (0.90-2.93)

.11

1.32 (0.76-2.32)

.33

alcohol, proton-pump inhibitor use, nonsteroidal anti-inflammatory ingestion, statin
use, T stage, N stage, R0 resection margin, chemotherapy and radiotherapy, and tumor
differentiation.

Abbreviations: HPV, human papillomavirus; HR, hazard ratio; mRNA, messenger RNA.
a

Model 1 was a univariate analysis on each characteristic with overall survival.

b

In model 2, each characteristic was analyzed in a multivariate Cox regression
separately, adjusted by the following covariates: age, sex, body mass index (calculated
as weight in kilograms divided by height in meters squared), ever smoked, excess

c

Model 3 was the same as model 2 but excluded the following covariates in the
adjustment: T stage, N stage, chemotherapy, and radiotherapy.
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modest sample size and associated comorbidities. These findings are somewhat similar to the data
in head and neck cancers. Human papillomavirus–positive HNSCCs have improved survival and lower
rate of local and regional recurrence compared with HPV-negative head and neck cancers. No
significant differences were detected in distant metastases, possibly because the studies were
insufficiently powered.21-23 In ESCC, it has been reported that patients with p16-positive cancers had
superior 5-year OS and PFS rates compared with patients with p16-negative cancers.24 Similarly,
Kumar and colleagues25 found that ESCC patients with p16-positive tumors subjected to neoadjuvant
chemotherapy had better complete remission rates than the p16-negative group. Conversely, in a
recent publication, HPV, p16, and p53 were not found to be prognostic factors in ESCC.26
The results of this study are consistent with our previous work that demonstrated HPV-positive
and HPV-negative EAC are distinct diseases just as in HNSCC. A previous study found that
HPV-positive EAC harbored approximately 50% fewer nonsilent somatic mutations than
HPV-negative EAC.8 Moreover, TP53 aberrations are less frequent in HPV-positive BD and EAC
compared with viral-negative esophageal lesions.7-9 Prior studies from our group have also
demonstrated that HPV-positive BD and EAC are mostly wild-type TP53.7,9 In this study, we similarly
found that only a quarter of HPV-positive HGD and EAC lesions harbored TP53 mutations vs
two-thirds of HPV-negative HGD and EAC having the same molecular aberration. Although patients
with EAC who have p53 mutations have been shown to have reduced OS in a recent meta-analysis,
we could not confirm the same in our study.27 Possible reasons include the small sample size and
other nonviral interactions involving p53 function, including smoking (which in this study was high in
both HPV-positive and HPV-negative patients) and alcohol use.28 Not surprisingly, comorbidity,
especially smoking related, also influences survival negatively.29 Response to chemotherapy in the
presence of other antiapoptotic proteins not analyzed in this study (eg, Bcl-2 and Bcl-xL, which are
associated with both chemotherapy and radiation resistance) could be another reason for this
discrepancy.30-32
Patients whose HGD and EAC harbored transcriptionally active HPV (n = 30) were significantly
younger (mean [SD] age, 61.4 [11.9] years) compared with patients with esophageal lesions devoid
of biologically active virus (n = 112) (mean [SD] age, 67.2 [11.9] years). This is in keeping with findings
from our previous small study on exome sequencing of HPV-positive and HPV-negative patients.8
Interestingly, three-quarters of HPV-positive esophageal lesions were early T stage (Tis, T1, and T2)
compared with slightly more than half of the HPV-negative group. Nevertheless, the vast majority of
both cohorts consisted of nodal stage N0 or N1 (89.2% of HPV-positive patients and 89.5% of viral
negative patients), which is probably indicative of patient selection for endotherapy or
esophagectomy with curative intent. Our results concur somewhat with data from HNSCC, another
malignant neoplasm in which a subset are HPV driven. Patients with HPV-positive HNSCC are
generally 10 years younger33 and have more early T-stage but advanced N-stage disease, although
they respond better to treatment and have a better outcome than patients with
HPV-negative HNSCC.34,35
The determination of HPV presence in BD or EAC can be difficult using FFPE specimens. While
PCR is more sensitive than ISH for HPV DNA detection, it risks false-positivity. Thus, in addition to
PCR for viral DNA, we also included E6 and E7 mRNA transcript analysis by ISH, which is a reliable
marker of HPV involvement, and IHC for p16 overexpression, a surrogate marker for HPV infection.
Sequencing and IHC for p53 were also undertaken given their importance in BD and EAC
progression.36 Central reporting of biopsy specimens by experienced gastrointestinal pathologists
was an added strength.

Limitations
This investigation was retrospective in nature and the study sample was small. The case-control
nature of the study introduces biases pertaining to selection, information, and observation as well as
confounding. As HPV status was not known at the time of enrollment and treatment decision, it
minimized both selection and observer bias. Measurement bias was addressed by blinding the
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scientist and pathologists to the clinical and virological status of the patients and to treatment
outcome. Confounding was mitigated with adjustment for potential confounders in the multivariate
statistical analysis. The independence of prognostic effects of the 5 dichotomous variables, HPV
DNA positivity, transcriptionally active HPV, E6 and E7 mRNA detection, and p16 and p53
overexpression, is important. Nevertheless, we could not include these variables in a single
multivariate model as they were intercorrelated. Thus, we were unable to identify the independent
effects of these factors. Some of the specimens analyzed were more than 10 years old, which
increases the risk of DNA and RNA invalidity. Moreover, IHC analysis is subjective and lacks uniform
scoring systems, which can hamper reproducibility between studies.

Conclusions
If these findings of a favorable prognosis of HPV-positive HGD and EAC are confirmed in larger
cohorts with more advanced disease, it presents an opportunity for treatment de-escalation in the
hope of reducing toxic effects without deleteriously affecting survival.
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